Myelosuppression by chemotherapy in obese patients with gynecological cancers

Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients

(2012) T. Miyahara et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2012) Jennifer J. Griggs et al.   JOURNAL OF CLINICAL ONCOLOGY

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants

(2011) Mariel M Finucane et al.   LANCET

Evaluation of Chemotherapy-Induced Severe Myelosuppression Incidence in Obese Patients With Capped Dosing

(2011) Monique D. Lopes-Serrao et al.   Journal of Oncology Practice

Effect of Obesity on the Pharmacokinetics of Drugs in Humans

(2010) Michael J. Hanley et al.   CLINICAL PHARMACOKINETICS

Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2

(2009) Joanna Schwartz et al.   GYNECOLOGIC ONCOLOGY

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

(2008) S. V. Barrett et al.   ANNALS OF ONCOLOGY

Carboplatin dosing in obese women with ovarian cancer: A Gynecologic Oncology Group study

(2008) Jason D. Wright et al.   GYNECOLOGIC ONCOLOGY